Test immunotherapy with salvage surgery and IORT for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have head and neck squamous cell cancer confirmed by biopsy (including oral cavity, throat, voice box, or unknown primary).
- Your cancer must be resectable, meaning the surgical team believes it can be removed.
- Your cancer should be measurable on CT or MRI scan.
- You must have had prior treatment (such as surgery, chemotherapy, and/or radiation) and now the cancer is persistent or has returned.
- Your blood tests must meet thresholds (white blood cells, neutrophils, platelets, and hemoglobin) and your liver and kidney function must be adequate within the last 14 days.
- You must be able to wait at least 2 weeks after your last treatment before starting this trial, and you must be willing/able to sign consent and attend follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This Phase 2 trial tests an immunotherapy given after salvage surgery for certain head and neck squamous cell cancers that came back (or a new second cancer) in an area that was already treated with radiation. It aims to lower the chance the cancer returns after surgery, especially in higher-risk situations.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
Hear when a new Locally Recurrent Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.